Specialty Drug Management
Speaker Interview
| David Twitchell, PharmD, MBA Vice President, Chief Pharmacy Officer Boston Medical Center |
|
| "Specialty drugs" refer to drugs that are complex which often treat fairly rare or life threatening conditions but also treat less rare, life altering ailments. Although the long term impact of these drugs is becoming more clear, they are often dismissed out of hand due to their cost. David Twitchell helps explain why that may be a mistake. | |
|
Listen Now!
|
|
With drug prices on the rise and specialty drugs accounting for over 30% of the total cost of drugs (yet representing less than 2% of all drugs), health plans must determine ways to manage the high prices of specialty prescriptions while maintaining high quality care.
This summit convenes health plans and other stakeholders to evaluate strategies for managing the high costs of specialty prescription drugs, in order to provide affordable, quality treatments and prescriptions to their members.
CLOSING KEYNOTE
Summarize Considerations Impacting Specialty Drug Management and Costs
The changing landscape of prescription drug utilization creates unique challenges for payers. The development and approval of more specialty drugs to the market requires Health Plans to consider multiple new factors in drug management including medical benefit strategies, provider payment structure, biosimilars, and outcomes based contracting. The changing regulatory environment also plays an important factor in managing this growing trend.
- Understand the growing specialty trend and challenges facing health plans
- Describe effective management strategies to mitigate these trends
- Discuss the future of specialty drugs and the regulatory impact
|
Top Reasons to Attend:
- Understand the drivers of medical specialty spend, how expenses change based on site of care, and examine shifts in site of care
- Recognize the data needed to mitigate overspending in the specialty realm
- Discuss how to best collaborate with various stakeholders to address cost concerns
- Identify how to get the right drug to the patient the first time, especially for high investment treatments
- Leverage 340B covered entity discounts with PBMs to gain access to better pricing and expanded specialty pharmacy networks
- Ensure the utilization of specialty drugs has a patient-centric focus
- Hear how to best manage the rising cost of oncology specialty drugs
- Recognize the data needed to mitigate overspending in the specialty realm
FEATURED PANEL DISCUSSION:
Why Are Specialty Drugs Special? Evaluate the Impact of Specialty Drugs on Patient Care
With the aging population and the increase in the number of patients with insurance coverage, the use of specialty drugs will become more pronounced. This will
require an increased focus on patient selection and value-based payment models. In this session, hear how specialty drugs can impact patient care and evaluate
ways to achieve quality outcomes at an affordable cost.
- Ensure that the utilization of specialty drugs is based on patient-centric criteria
- Discuss what patients and payers need to know about specialty drugs and limited distribution channels
- Evaluate important quality outcomes and determine how to partner with all stakeholders to achieve these outcomes
Panelists:
|
|
||||
|
The Specialty Drug Management Summit shares sessions with the Health Plan Medication Adherence Summit:
Part of our Health Care Consumer Engagement Congress
500 West Cummings Park, Suite 5400
800-767-9499
wcreg@worldcongress.com
Sitemap
